Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective Multicenter Real-world Study of Surufatinib in Advanced Neuroendocrine Neoplasms
ChiCTR2500114518Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Dec 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of surufatinib in apudoma (NET), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Progression-Free Survival. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
surufatinib
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on ChiCTR2500114518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114518.